Merck's Keytruda Sales Soar 21% as Cancer Treatment Remains Top Earner
Merck's cancer treatment Keytruda is in the spotlight after strong quarterly earnings. The company reported that sales of the immunotherapy drug rose 21% year-over-year, reaching $6.4 billion in revenue.
This growth has some investors optimistic about Merck's future prospects. 'The strong performance of Keytruda is a testament to its value as a treatment option for patients with advanced cancer,' said an analyst. However, not everyone is convinced that the stock is a good buy. Some experts caution that the high price of Keytruda may be a barrier to adoption.
The company's earnings report also highlighted the increasing importance of Keytruda in Merck's overall business. The drug now accounts for over 40% of the company's total revenue, up from around 30% just two years ago.